Zinc and diabetes mellitus: understanding molecular mechanisms and clinical implications

Priyanga Ranasinghe, Shehani Pigera, Priyadarshani Galappatthy, Prasad Katulanda, Godwin R Constantine, Priyanga Ranasinghe, Shehani Pigera, Priyadarshani Galappatthy, Prasad Katulanda, Godwin R Constantine

Abstract

Background: Diabetes mellitus is a leading cause of morbidity and mortality worldwide. Studies have shown that Zinc has numerous beneficial effects in both type-1 and type-2 diabetes. We aim to evaluate the literature on the mechanisms and molecular level effects of Zinc on glycaemic control, β-cell function, pathogenesis of diabetes and its complications.

Methods: A review of published studies reporting mechanisms of action of Zinc in diabetes was undertaken in PubMed and SciVerse Scopus medical databases using the following search terms in article title, abstract or keywords; ("Zinc" or "Zn") and ("mechanism" or "mechanism of action" or "action" or "effect" or "pathogenesis" or "pathology" or "physiology" or "metabolism") and ("diabetes" or "prediabetes" or "sugar" or "glucose" or "insulin").

Results: The literature search identified the following number of articles in the two databases; PubMed (n = 1799) and SciVerse Scopus (n = 1879). After removing duplicates the total number of articles included in the present review is 111. Our results show that Zinc plays an important role in β-cell function, insulin action, glucose homeostasis and the pathogenesis of diabetes and its complications.

Conclusion: Numerous in-vitro and in-vivo studies have shown that Zinc has beneficial effects in both type-1 and type-2 diabetes. However further randomized double-blinded placebo-controlled clinical trials conducted for an adequate duration, are required to establish therapeutic safety in humans.

Figures

Fig. 1
Fig. 1
Summarized search strategy

References

    1. IDF Diabetes Atlas - The Economic Impacts of Diabetes. []
    1. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005;365(9467):1333–1346. doi: 10.1016/S0140-6736(05)61032-X.
    1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–1053. doi: 10.2337/diacare.27.5.1047.
    1. WHO Diabetes Fact Sheet. []
    1. Diabetes: the cost of diabetes []
    1. Stuckler D. Population Causes and Consequences of Leading Chronic Diseases: A Comparative Analysis of Prevailing Explanations. The Milbank Quarterly. 2008;86(2):273–326. doi: 10.1111/j.1468-0009.2008.00522.x.
    1. Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in U.S. diabetes care 1999–2010. N Engl J Med. 2013;368(17):1613–1624. doi: 10.1056/NEJMsa1213829.
    1. Khunti K, Davies M. Glycaemic goals in patients with type 2 diabetes: current status, challenges and recent advances. Diabetes Obes Metab. 2010;12(6):474–484. doi: 10.1111/j.1463-1326.2009.01186.x.
    1. Dodson G, Steiner D. The role of assembly in insulin's biosynthesis. Curr Opin Struct Biol. 1998;8(2):189–194. doi: 10.1016/S0959-440X(98)80037-7.
    1. Simon SF, Taylor CG. Dietary zinc supplementation attenuates hyperglycemia in db/db mice. Exp Biol Med (Maywood) 2001;226(1):43–51.
    1. Faure P, Benhamou PY, Perard A, Halimi S, Roussel AM. Lipid peroxidation in insulin-dependent diabetic patients with early retina degenerative lesions: effects of an oral zinc supplementation. Eur J Clin Nutr. 1995;49(4):282–288.
    1. Shidfar F, Aghasi M, Vafa M, Heydari I, Hosseini S, Shidfar S. Effects of combination of zinc and vitamin A supplementation on serum fasting blood sugar, insulin, apoprotein B and apoprotein A-I in patients with type i diabetes. Int J Food Sci Nutr. 2010;61(2):182–191. doi: 10.3109/09637480903334171.
    1. Afkhami-Ardekani M, Karimi M, Mohammadi SM, Nourani F. Effect of zinc sulfate supplementation on lipid and glucose in type 2 diabetic patients. Pak J Nutr. 2008;7(4):550–553. doi: 10.3923/pjn.2008.550.553.
    1. Al-Maroof RA, Al-Sharbatti SS. Serum zinc levels in diabetic patients and effect of zinc supplementation on glycemic control of type 2 diabetics. Saudi Med J. 2006;27(3):344–350.
    1. Jayawardena R, Ranasinghe P, Galappatthy P, Malkanthi R, Constantine G, Katulanda P. Effects of zinc supplementation on diabetes mellitus: a systematic review and meta-analysis. Diabetol Metab Syndr. 2012;4(1):13. doi: 10.1186/1758-5996-4-13.
    1. Garg VK, Gupta R, Goyal RK. Hypozincemia in diabetes mellitus. J Assoc Physicians India. 1994;42(9):720–721.
    1. Pidduck HG, Wren PJ, Evans DA. Hyperzincuria of diabetes mellitus and possible genetical implications of this observation. Diabetes. 1970;19(4):240–247. doi: 10.2337/diab.19.4.240.
    1. Black RE. Zinc deficiency, infectious disease and mortality in the developing world. J Nutr. 2003;133(5 Suppl 1):1485S–1489S.
    1. Anderson RA, Roussel AM, Zouari N, Mahjoub S, Matheau JM, Kerkeni A. Potential antioxidant effects of zinc and chromium supplementation in people with type 2 diabetes mellitus. J Am Coll Nutr. 2001;20(3):212–218. doi: 10.1080/07315724.2001.10719034.
    1. Blostein-Fujii A, DiSilvestro RA, Frid D, Katz C, Malarkey W. Short-term zinc supplementation in women with non-insulin-dependent diabetes mellitus: effects on plasma 5'-nucleotidase activities, insulin-like growth factor I concentrations, and lipoprotein oxidation rates in vitro. Am J Clin Nutr. 1997;66(3):639–642.
    1. Pathak A, Sharma V, Kumar S, Dhawan DK. Supplementation of zinc mitigates the altered uptake and turnover of 65Zn in liver and whole body of diabetic rats. Biometals. 2011;24(6):1027–1034. doi: 10.1007/s10534-011-9461-2.
    1. Konukoglu D, Turhan MS, Ercan M, Serin O. Relationship between plasma leptin and zinc levels and the effect of insulin and oxidative stress on leptin levels in obese diabetic patients. J Nutr Biochem. 2004;15(12):757–760. doi: 10.1016/j.jnutbio.2004.07.007.
    1. Faure P, Barclay D, Joyeux-Faure M, Halimi S. Comparison of the effects of zinc alone and zinc associated with selenium and vitamin E on insulin sensitivity and oxidative stress in high-fructose-fed rats. J Trace Elem Med Biol. 2007;21(2):113–119. doi: 10.1016/j.jtemb.2006.12.005.
    1. Vijayaraghavan K, Iyyampillai S, Subramanian SP. Antioxidant potential of zinc-flavonol complex studied in streptozotocin-diabetic rats. J Diabetes. 2013;5(2):149–156. doi: 10.1111/j.1753-0407.2012.00226.x.
    1. Bădescu M, Păduraru I, Colev V, Saramet A, Bohotin C, Bădescu L. The relation zinc-lipidic peroxidation in experimental diabetes mellitus. Rom J Physiol. 1993;30(3–4):167–171.
    1. Duzguner V, Kaya S. Effect of zinc on the lipid peroxidation and the antioxidant defense systems of the alloxan-induced diabetic rabbits. Free Radic Biol Med. 2007;42(10):1481–1486. doi: 10.1016/j.freeradbiomed.2007.02.021.
    1. Tang Y, Yang Q, Lu J, Zhang X, Suen D, Tan Y, et al. Zinc supplementation partially prevents renal pathological changes in diabetic rats. J Nutr Biochem. 2010;21(3):237–46.
    1. Wang X, Li H, Fan Z, Liu Y. Effect of zinc supplementation on type 2 diabetes parameters and liver metallothionein expressions in Wistar rats. J Physiol Biochem. 2012;68(4):563–572. doi: 10.1007/s13105-012-0174-y.
    1. Moustafa SA. Zinc might protect oxidative changes in the retina and pancreas at the early stage of diabetic rats. Toxicol Appl Pharmacol. 2004;201(2):149–155. doi: 10.1016/j.taap.2004.05.014.
    1. Ohly P, Dohle C, Abel J, Seissler J, Gleichmann H. Zinc sulphate induces metallothionein in pancreatic islets of mice and protects against diabetes induced by multiple low doses of streptozotocin. Diabetologia. 2000;43(8):1020–1030. doi: 10.1007/s001250050009.
    1. Özcelik D, Nazıroglu M, Tunçdemir M, Çelik Ö, Öztürk M, Flores-Arce MF. Zinc supplementation attenuates metallothionein and oxidative stress changes in kidney of streptozotocin-induced diabetic rats. Biol Trace Elem Res. 2012;150(1–3):342–349. doi: 10.1007/s12011-012-9508-4.
    1. Zimny S, Gogolin F, Abel J, Gleichmann H. Metallothionein in isolated pancreatic islets of mice: induction by zinc and streptozotocin, a naturally occurring diabetogen. Arch Toxicol. 1993;67(1):61–65. doi: 10.1007/BF02072037.
    1. Wang J, Song Y, Elsherif L, Song Z, Zhou G, Prabhu SD, et al. Cardiac metallothionein induction plays the major role in the prevention of diabetic cardiomyopathy by zinc supplementation. Circulation. 2006;113(4):544–54.
    1. Liang T, Zhang Q, Sun W, Xin Y, Zhang Z, Tan Y, et al. Zinc treatment prevents type 1 diabetes-induced hepatic oxidative damage, endoplasmic reticulum stress, and cell death, and even prevents possible steatohepatitis in the OVE26 mouse model: Important role of metallothionein. Toxicol Lett. 2015;233(2):114–24.
    1. Lu Y, Liu Y, Li H, Wang X, Wu W, Gao L. Effect and mechanisms of zinc supplementation in protecting against diabetic cardiomyopathy in a rat model of type 2 diabetes. Bosn J Basic Med Sci. 2015;15(1):14–20. doi: 10.17305/bjbms.2015.63.
    1. Zhang X, Liang D, Chi ZH, Chu Q, Zhao C, Ma RZ, et al. Effect of zinc on high glucose-induced epithelial-to-mesenchymal transition in renal tubular epithelial cells. Int J Mol Med. 2015;35(6):1747–54.
    1. Liu F, Ma F, Kong G, Wu K, Deng Z, Wang H. Zinc supplementation alleviates diabetic peripheral neuropathy by inhibiting oxidative stress and upregulating metallothionein in peripheral nerves of diabetic rats. Biol Trace Elem Res. 2014;158(2):211–218. doi: 10.1007/s12011-014-9923-9.
    1. Miao X, Wang Y, Sun J, Sun W, Tan Y, Cai L, et al. Zinc protects against diabetes-induced pathogenic changes in the aorta: Roles of metallothionein and nuclear factor (erythroid-derived 2)-like 2. Cardiovasc Diabetol. 2013;12:54.
    1. Li B, Cui W, Tan Y, Luo P, Chen Q, Zhang C, et al. Zinc is essential for the transcription function of Nrf2 in human renal tubule cells in vitro and mouse kidney in vivo under the diabetic condition. J Cell Mol Med. 2014;18(5):895–906.
    1. Zhang X, Zhao Y, Chu Q, Wang ZY, Li H, Chi ZH. Zinc modulates high glucose-induced apoptosis by suppressing oxidative stress in renal tubular epithelial cells. Biol Trace Elem Res. 2014;158(2):259–267. doi: 10.1007/s12011-014-9922-x.
    1. Chu A, Foster M, Hancock D, Bell-Anderson K, Petocz P, Samman S. TNF-alpha gene expression is increased following zinc supplementation in type 2 diabetes mellitus. Genes & nutrition. 2015;10(1):440. doi: 10.1007/s12263-014-0440-4.
    1. Brand IA, Kleineke J. Intracellular zinc movement and its effect on the carbohydrate metabolism of isolated rat hepatocytes. J Biol Chem. 1996;271(4):1941–1949. doi: 10.1074/jbc.271.4.1941.
    1. Shisheva A, Gefel D, Shechter Y. Insulinlike effects of zinc ion in vitro and in vivo. Preferential effects on desensitized adipocytes and induction of normoglycemia in streptozocin-induced rats. Diabetes. 1992;41(8):982–988. doi: 10.2337/diab.41.8.982.
    1. May JM, Contoreggi CS. The mechanism of the insulin-like effects of ionic zinc. J Biol Chem. 1982;257(8):4362–4368.
    1. Canesi L, Betti M, Ciacci C, Gallo G. Insulin-like effect of zinc in mytilus digestive gland cells: modulation of tyrosine kinase-mediated cell signaling. Gen Comp Endocrinol. 2001;122(1):60–66. doi: 10.1006/gcen.2001.7612.
    1. Tamaki N, Ikeda T, Funatsuka A. Zinc as activating cation for muscle glycolysis. J Nutr Sci Vitaminol. 1983;29(6):655–662. doi: 10.3177/jnsv.29.655.
    1. Filippi C, Pryde A, Cowan P, Lee T, Hayes P, Donaldson K, et al. Toxicology of ZnO and TiO2 nanoparticles on hepatocytes: impact on metabolism and bioenergetics. Nanotoxicology. 2015;9(1):126–34.
    1. Yoshikawa Y, Hirata R, Yasui H, Sakurai H. Alpha-glucosidase inhibitory effect of anti-diabetic metal ions and their complexes. Biochimie. 2009;91(10):1339–1341. doi: 10.1016/j.biochi.2009.06.005.
    1. Zeng YF, Lee J, Si YX, Yan L, Kim TR, Qian GY, et al. Inhibitory effect of Zn2+ on α-glucosidase: Inhibition kinetics and molecular dynamics simulation. Process Biochem. 2012;47(12):2510–7.
    1. Eckardt K, Schober A, Platzbecker B, Mracek T, Bing C, Trayhurn P, et al. The adipokine zinc-α2-glycoprotein activates AMP kinase in human primary skeletal muscle cells. Arch Physiol Biochem. 2011;117(2):88–93.
    1. Russell ST, Tisdale MJ. Studies on the anti-obesity activity of zinc-α 2-glycoprotein in the rat. Int J Obes (Lond) 2011;35(5):658–665. doi: 10.1038/ijo.2010.193.
    1. Miranda ER, Dey CS. Effect of chromium and zinc on insulin signaling in skeletal muscle cells. Biol Trace Elem Res. 2004;101(1):19–36. doi: 10.1385/BTER:101:1:19.
    1. Balaz M, Vician M, Janakova Z, Kurdiova T, Surova M, Imrich R, et al. Subcutaneous adipose tissue zinc-alpha2-glycoprotein is associated with adipose tissue and whole-body insulin sensitivity. Obesity (Silver Spring, Md). 2014;22(8):1821–9.
    1. Ceperuelo-Mallafre V, Ejarque M, Duran X, Pachon G, Vazquez-Carballo A, Roche K, et al. Zinc-alpha2-glycoprotein modulates AKT-dependent insulin signaling in human adipocytes by activation of the PP2A phosphatase. PLoS One. 2015;10(6):e0129644.
    1. Buchner DA, Charrier A, Srinivasan E, Wang L, Paulsen MT, Ljungman M, et al. Zinc finger protein 407 (ZFP407) regulates insulin-stimulated glucose uptake and glucose transporter 4 (Glut4) mRNA. J Biol Chem. 2015;290(10):6376–86.
    1. Tang X, Shay NF. Zinc has an insulin-like effect on glucose transport mediated by phosphoinositol-3-kinase and Akt in 3 T3-L1 fibroblasts and adipocytes. J Nutr. 2001;131(5):1414–1420.
    1. Ilouz R, Kaidanovich O, Gurwitz D, Eldar-Finkelman H. Inhibition of glycogen synthase kinase-3beta by bivalent zinc ions: insight into the insulin-mimetic action of zinc. Biochem Biophys Res Commun. 2002;295(1):102–106. doi: 10.1016/S0006-291X(02)00636-8.
    1. Ezaki O. IIb group metal ions (Zn2+, Cd2+, Hg2+) stimulate glucose transport activity by post-insulin receptor kinase mechanism in rat adipocytes. J Biol Chem. 1989;264(27):16118–16122.
    1. Coulston L, Dandona P. Insulin-like effect of zinc on adipocytes. Diabetes. 1980;29(8):665–667. doi: 10.2337/diab.29.8.665.
    1. Herington AC. Effect of zinc on insulin binding to rat adipocytes and hepatic membranes and to human placental membranes and IM-9 lymphocytes. Horm Metab Res. 1985;17(7):328–332.
    1. Ghosh C, Yang SH, Kim JG, Jeon TI, Yoon BH, Lee JY, et al. Zinc-chelated vitamin C stimulates adipogenesis of 3 T3-L1 cells. Asian-Australas J Anim Sci. 2013;26(8):1189–96.
    1. Gomot MJ, Faure P, Roussel AM, Coudray C, Osman M, Favier A. Effect of acute zinc deficiency on insulin receptor binding in rat adipocytes. Biol Trace Elem Res. 1992;32:331–335. doi: 10.1007/BF02784619.
    1. Aspinwall CA, Brooks SA, Kennedy RT, Lakey JR. Effects of intravesicular H+ and extracellular H+ and Zn2+ on insulin secretion in pancreatic beta cells. J. Biol. Chem. 1997;272(50):31308–31314. doi: 10.1074/jbc.272.50.31308.
    1. Slepchenko KG, James CB, Li YV. Inhibitory effect of zinc on glucose-stimulated zinc/insulin secretion in an insulin-secreting beta-cell line. Exp Physiol. 2013;98(8):1301–1311. doi: 10.1113/expphysiol.2013.072348.
    1. Slepchenko KG, Daniels NA, Guo A, Li YV. Autocrine effect of Zn on the glucose-stimulated insulin secretion. Endocrine. 2015;50:110–122. doi: 10.1007/s12020-015-0568-z.
    1. Bellomo EA, Meur G, Rutter GA. Glucose regulates free cytosolic Zn2+ concentration, Slc39 (ZiP), and metallothionein gene expression in primary pancreatic islet β-cells. J. Biol. Chem. 2011;286(29):25778–25789. doi: 10.1074/jbc.M111.246082.
    1. Slepchenko KG, Li YV. Rising intracellular zinc by membrane depolarization and glucose in insulin-secreting clonal HIT-T15 beta cells. Exp Diabetes Res. 2012;2012:190309–9.
    1. Brender JR, Hartman K, Nanga RPR, Popovych N, De La Salud BR, Vivekanandan S, et al. Role of zinc in human islet amyloid polypeptide aggregation. J Am Chem Soc. 2010;132(26):8973–83.
    1. Chimienti F, Devergnas S, Pattou F, Schult F, Garcia-Cuenca R, Vandewalle B, et al. In vivo expression and functional characterization of the zinc transporter ZnT8 in glucose-induced insulin secretion. J Cell Sci. 2006;119(20):4199–206.
    1. Chimienti F, Devergnas S, Favier A, Seve M. Identification and cloning of a beta-cell-specific zinc transporter, ZnT-8, localized into insulin secretory granules. Diabetes. 2004;53(9):2330–2337. doi: 10.2337/diabetes.53.9.2330.
    1. Chimienti F, Favier A, Seve M. ZnT-8, a pancreatic beta-cell-specific zinc transporter. Biometals. 2005;18(4):313–317. doi: 10.1007/s10534-005-3687-9.
    1. Wijesekara N, Dai FF, Hardy AB, Giglou PR, Bhattacharjee A, Koshkin V, et al. Beta cell-specific Znt8 deletion in mice causes marked defects in insulin processing, crystallisation and secretion. Diabetologia. 2010;53(8):1656–68.
    1. Nicolson TJ, Bellomo EA, Wijesekara N, Loder MK, Baldwin JM, Gyulkhandanyan AV, et al. Insulin storage and glucose homeostasis in mice null for the granule zinc transporter ZnT8 and studies of the type 2 diabetes-associated variants. Diabetes. 2009;58(9):2070–83.
    1. Fu Y, Tian W, Pratt EB, Dirling LB, Shyng S-L, Meshul CK, et al. Down-regulation of ZnT8 expression in INS-1 rat pancreatic beta cells reduces insulin content and glucose-inducible insulin secretion. PLoS One. 2009;4(5):e5679–9.
    1. Lemaire K, Ravier MA, Schraenen A, Creemers JWM, Van de Plas R, Granvik M, et al. Insulin crystallization depends on zinc transporter ZnT8 expression, but is not required for normal glucose homeostasis in mice. Proc Natl Acad Sci U S A. 2009;106(35):14872–7.
    1. Pound LD, Sarkar SA, Benninger RKP, Wang Y, Suwanichkul A, Shadoan MK, et al. Deletion of the mouse Slc30a8 gene encoding zinc transporter-8 results in impaired insulin secretion. Biochem J. 2009;421(3):371–6.
    1. Pound LD, Sarkar SA, Ustione A, Dadi PK, Shadoan MK, Lee CE, et al. The physiological effects of deleting the mouse SLC30A8 gene encoding zinc transporter-8 are influenced by gender and genetic background. PLoS One. 2012;7(7):e40972–2.
    1. Lefebvre B, Vandewalle B, Balavoine AS, Queniat G, Moerman E, Vantyghem MC, et al. Regulation and functional effects of ZNT8 in human pancreatic islets. J Endocrinol. 2012;214(2):225–32.
    1. Liu B-Y, Jiang Y, Lu Z, Li S, Lu D, Chen B. Down-regulation of zinc transporter 8 in the pancreas of db/db mice is rescued by Exendin-4 administration. Mol Med Rep. 2011;4(1):47–52.
    1. Tamaki M, Fujitani Y, Hara A, Uchida T, Tamura Y, Takeno K, et al. The diabetes-susceptible gene SLC30A8/ZnT8 regulates hepatic insulin clearance. J Clin Invest. 2013;123(10):4513–24.
    1. Gerber PA, Bellomo EA, Hodson DJ, Meur G, Solomou A, Mitchell RK, et al. Hypoxia lowers SLC30A8/ZnT8 expression and free cytosolic Zn2+ in pancreatic beta cells. Diabetologia. 2014;57(8):1635–44.
    1. Pae EK, Kim G. Insulin production hampered by intermittent hypoxia via impaired zinc homeostasis. PLoS One. 2014;9(2):e90192. doi: 10.1371/journal.pone.0090192.
    1. Liu Y, Batchuluun B, Ho L, Zhu D, Prentice KJ, Bhattacharjee A, et al. Characterization of zinc influx transporters (ZIPS) in pancreatic beta cells: roles in regulating cytosolic zinc homeostasis and insulin secretion. J Biol Chem. 2015;290(30):18757–69.
    1. Hardy AB, Prentice KJ, Froese S, Liu Y, Andrews GK, Wheeler MB. Zip4 mediated zinc influx stimulates insulin secretion in pancreatic beta cells. PLoS One. 2015;10(3):e0119136. doi: 10.1371/journal.pone.0119136.
    1. Smidt K, Jessen N, Petersen AB, Larsen A, Magnusson N, Jeppesen JB, et al. SLC30A3 responds to glucose- and zinc variations in beta-cells and is critical for insulin production and in vivo glucose-metabolism during beta-cell stress. PLoS One. 2009;4(5):e5684–4.
    1. Myers SA, Nield A, Chew GS, Myers MA. The zinc transporter, Slc39a7 (Zip7) is implicated in glycaemic control in skeletal muscle cells. PLoS One. 2013;8(11):e79316. doi: 10.1371/journal.pone.0079316.
    1. Gyulkhandanyan AV, Lee SC, Bikopoulos G, Dai F, Wheeler MB. The Zn2 + −transporting pathways in pancreatic β-cells: A role for the L-type voltage-gated Ca2+ channel. J Biol Chem. 2006;281(14):9361–9372. doi: 10.1074/jbc.M508542200.
    1. Wagner TFJ, Drews A, Loch S, Mohr F, Philipp SE, Lambert S, et al. TRPM3 channels provide a regulated influx pathway for zinc in pancreatic beta cells. Pflugers Arch. 2010;460(4):755–65.
    1. Duprez J, Roma LP, Close A-F, Jonas J-C. Protective antioxidant and antiapoptotic effects of ZnCl2 in rat pancreatic islets cultured in low and high glucose concentrations. PLoS One. 2012;7(10):e46831–1.
    1. Shoae-Hagh P, Rahimifard M, Navaei-Nigjeh M, Baeeri M, Gholami M, Mohammadirad A, et al. Zinc oxide nanoparticles reduce apoptosis and oxidative stress values in isolated rat pancreatic islets. Biol Trace Elem Res. 2014;162(1–3):262–9.
    1. Manna PT, Munsey TS, Abuarab N, Li F, Asipu A, Howell G, et al. TRPM2-mediated intracellular Zn2+ release triggers pancreatic beta-cell death. Biochem J. 2015;466(3):537–46.
    1. Henry C, Close AF, Buteau J. A critical role for the neural zinc factor ST18 in pancreatic beta-cell apoptosis. J Biol Chem. 2014;289(12):8413–8419. doi: 10.1074/jbc.M114.554915.
    1. Gyulkhandanyan AV, Lu H, Lee SC, Bhattacharjee A, Wijesekara N, Fox JEM, et al. Investigation of transport mechanisms and regulation of intracellular Zn2+ in pancreatic alpha-cells. J Biol Chem. 2008;283(15):10184–97.
    1. Zhou H, Zhang T, Harmon JS, Bryan J, Robertson RP. Zinc, not insulin, regulates the rat alpha-cell response to hypoglycemia in vivo. Diabetes. 2007;56(4):1107–1112. doi: 10.2337/db06-1454.
    1. Slucca M, Harmon JS, Oseid EA, Bryan J, Robertson RP. ATP-sensitive K+ channel mediates the zinc switch-off signal for glucagon response during glucose deprivation. Diabetes. 2010;59(1):128–134. doi: 10.2337/db09-1098.
    1. Yoshikawa Y, Ueda E, Miyake H, Sakurai H, Kojima Y. Insulinomimetic bis(maltolato)zinc(II) complex: blood glucose normalizing effect in KK-A(y) mice with type 2 diabetes mellitus. Biochem Biophys Res Commun. 2001;281(5):1190–1193. doi: 10.1006/bbrc.2001.4456.
    1. Yoshikawa Y, Ueda E, Suzuki Y, Yanagihara N, Sakurai H, Kojima Y. New insulinomimetic zinc(II) complexes of alpha-amino acids and their derivatives with Zn(N2O2) coordination mode. Chem Pharm Bull. 2001;49(5):652–654. doi: 10.1248/cpb.49.652.
    1. Ueda E, Yoshikawa Y, Ishino Y, Sakurai H, Kojima Y. Potential insulinominetic agents of zinc(II) complexes with picolinamide derivatives: preparations of complexes, in vitro and in vivo studies. Chem Pharm Bull. 2002;50(3):337–340. doi: 10.1248/cpb.50.337.
    1. Yoshikawa Y, Ueda E, Sakurai H, Kojima Y. Anti-diabetes effect of Zn(II)/carnitine complex by oral administration. Chem Pharm Bull. 2003;51(2):230–231. doi: 10.1248/cpb.51.230.
    1. Adachi Y, Yoshida J, Kodera Y, Kato A, Yoshikawa Y, Kojima Y, et al. A new insulin-mimetic bis(allixinato)zinc(II) complex: structure-activity relationship of zinc(II) complexes. J Biol Inorg Chem. 2004;9(7):885–93.
    1. Yoshikawa Y, Ueda E, Kojima Y, Sakurai H. The action mechanism of zinc(II) complexes with insulinomimetic activity in rat adipocytes. Life Sci. 2004;75(6):741–751. doi: 10.1016/j.lfs.2004.02.006.
    1. Kojima Y, Yoshikawa Y, Ueda E, Kishimoto N, Tadokoro M, Sakurai H. Synthesis, structure, and in vitro and in vivo insulinomimetic activities of the zinc(II)-6-ethylpicolinate complex. Bull Chem Soc Jpn. 2005;78(3):451–455. doi: 10.1246/bcsj.78.451.
    1. Yoshikawa Y, Kondo M, Sakurai H, Kojima Y. A family of insulinomimetic zinc(II) complexes of amino ligands with Zn(Nn) (n = 3 and 4) coordination modes. J Inorg Biochem. 2005;99(7):1497–1503. doi: 10.1016/j.jinorgbio.2005.04.011.
    1. Adachi Y, Yoshikawa Y, Sakurai H. Antidiabetic zinc(II)-N-acetyl-L-cysteine complex: evaluations of in vitro insulinomimetic and in vivo blood glucose-lowering activities. Biofactors (Oxford, England) 2007;29(4):213–223. doi: 10.1002/biof.5520290405.
    1. Basuki W, Hiromura M, Sakurai H. Insulinomimetic Zn complex (Zn(opt)2) enhances insulin signaling pathway in 3 T3-L1 adipocytes. J Inorg Biochem. 2007;101(4):692–699. doi: 10.1016/j.jinorgbio.2006.12.015.
    1. Yoshikawa Y, Adachi Y, Sakurai H. A new type of orally active anti-diabetic Zn(II)-dithiocarbamate complex. Life Sci. 2007;80(8):759–766. doi: 10.1016/j.lfs.2006.11.003.
    1. Nakayama A, Hiromura M, Adachi Y, Sakurai H. Molecular mechanism of Antidiabetic zinc-allixin complexes: regulations of glucose utilization and lipid metabolism. J Biol Inorg Chem. 2008;13(5):675–684. doi: 10.1007/s00775-008-0352-0.
    1. Nishide M, Yoshikawa Y, Yoshikawa EU, Matsumoto K, Sakurai H, Kajiwara NM. Insulinomimetic Zn(II) complexes as evaluated by both glucose-uptake activity and inhibition of free fatty acids release in isolated rat adipocytes. Chem Pharm Bull. 2008;56(8):1181–1183. doi: 10.1248/cpb.56.1181.
    1. Rasheed K, Tariq MI, Munir C, Hussain I, Siddiqui HL. Synthesis, characterization and hypoglycemic activity of Zn(II), Cd(II) and Hg(II) complexes with glibenclamide. Chem Pharm Bull. 2008;56(2):168–172. doi: 10.1248/cpb.56.168.
    1. Karmaker S, Saha TK, Yoshikawa Y, Sakurai H. A zinc(II)/poly(γ-glutamic acid) complex as an oral therapeutic for the treatment of type-2 diabetic KKAy mice. Macromol Biosci. 2009;9(3):279–286. doi: 10.1002/mabi.200800190.
    1. Matsumoto K, Motoyasu N, Sera K, Fujii T, Yoshikawa Y, Yasui H, et al. Effects of Zn(II) complex with vitamins C and U, and carnitine on metabolic syndrome model rats. Metallomics. 2011;3(7):683–5.
    1. Moniz T, Amorim MJ, Ferreira R, Nunes A, Silva A, Queirós C, et al. Investigation of the insulin-like properties of zinc(II) complexes of 3-hydroxy-4-pyridinones: identification of a compound with glucose lowering effect in STZ-induced type I diabetic animals. J Inorg Biochem. 2011;105(12):1675–82.
    1. Naito Y, Yoshikawa Y, Yasui H. Cellular mechanism of zinchinokitiol complexes in diabetes mellitus. Bull Chem Soc Jpn. 2011;84(3):298–305. doi: 10.1246/bcsj.20100262.
    1. Yoshikawa Y, Adachi Y, Yasui H, Hattori M, Sakurai H. Oral administration of Bis(aspirinato)zinc(II) complex ameliorates hyperglycemia and metabolic syndrome-like disorders in spontaneously diabetic KK-A(y) mice: structure-activity relationship on zinc-salicylate complexes. Chem Pharm Bull. 2011;59(8):972–977. doi: 10.1248/cpb.59.972.
    1. Vijayaraghavan K, Iyyam Pillai S, Subramanian SP. Design, synthesis and characterization of zinc-3 hydroxy flavone, a novel zinc metallo complex for the treatment of experimental diabetes in rats. Eur J Pharmacol. 2012;680(1–3):122–129. doi: 10.1016/j.ejphar.2012.01.022.
    1. Fujimoto S, Yasui H, Yoshikawa Y. Development of a novel antidiabetic zinc complex with an organoselenium ligand at the lowest dosage in KK-A(y) mice. J Inorg Biochem. 2013;121:10–15. doi: 10.1016/j.jinorgbio.2012.12.008.
    1. Kadowaki S, Munekane M, Kitamura Y, Hiromura M, Kamino S, Yoshikawa Y, et al. Development of new zinc dithiosemicarbazone complex for use as oral antidiabetic agent. Biol Trace Elem Res. 2013;154(1):111–9.
    1. Alkaladi A, Abdelazim AM, Afifi M. Antidiabetic activity of zinc oxide and silver nanoparticles on streptozotocin-induced diabetic rats. Int J Mol Sci. 2014;15(2):2015–2023. doi: 10.3390/ijms15022015.
    1. Umrani RD, Paknikar KM. Zinc oxide nanoparticles show antidiabetic activity in streptozotocin-induced Type 1 and 2 diabetic rats. Nanomedicine (Lond) 2014;9(1):89–104. doi: 10.2217/nnm.12.205.
    1. Chen MD, Song YM, Lin PY. Zinc effects on hyperglycemia and hypoleptinemia in streptozotocin-induced diabetic mice. Horm Metab Res. 2000;32(3):107–109. doi: 10.1055/s-2007-978600.
    1. Liu MJ, Bao S, Bolin ER, Burris DL, Xu X, Sun Q, et al. Zinc deficiency augments leptin production and exacerbates macrophage infiltration into adipose tissue in mice fed a high-fat diet. J Nutr. 2013;143(7):1036–45.
    1. Kanoh Y, Tomotsune D, Shirasawa S, Yoshie S, Ichikawa H, Yokoyama T, et al. In vitro transdifferentiation of HepG2 cells to pancreatic-like cells by CCl4, D-galactosamine, and ZnCl2. Pancreas. 2011;40(8):1245–52.
    1. Meyer JA, Subasinghe W, Sima AAF, Keltner Z, Reid GE, Daleke D, et al. Zinc-activated C-peptide resistance to the type 2 diabetic erythrocyte is associated with hyperglycemia-induced phosphatidylserine externalization and reversed by metformin. Mol Biosyst. 2009;5(10):1157–62.
    1. Bortolin RH, da Graca Azevedo Abreu BJ, Abbott Galvao Ururahy M, de Souza KS C, Bezerra JF, Loureiro MB, et al. Protection against T1DM-induced bone loss by zinc supplementation: biomechanical, histomorphometric, and molecular analyses in STZ-induced diabetic rats. PLoS One. 2015;10(5):e0125349.
    1. Xiong M, Liu L, Liu Z, Gao H. Inhibitory effect of zinc on the advanced glycation end product-induced apoptosis of mouse osteoblastic cells. Molecular medicine reports 2015. 10.3892/mmr.2015.4088.
    1. Tupe R, Kulkarni A, Adeshara K, Sankhe N, Shaikh S, Dalal S, et al. Zinc inhibits glycation induced structural, functional modifications in albumin and protects erythrocytes from glycated albumin toxicity. Int J Biol Macromol. 2015;79:601–10.
    1. Baraka-Vidot J, Navarra G, Leone M, Bourdon E, Militello V, Rondeau P. Deciphering metal-induced oxidative damages on glycated albumin structure and function. Biochim Biophys Acta. 2014;1840(6):1712–1724. doi: 10.1016/j.bbagen.2013.12.017.
    1. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107(9):1058–1070. doi: 10.1161/CIRCRESAHA.110.223545.
    1. Ranasinghe P, Wathurapatha WS, Ishara MH, Jayawardana R, Galappatthy P, Katulanda P, et al. Effects of Zinc supplementation on serum lipids: a systematic review and meta-analysis. Nutr Metab. 2015;12:26.
    1. Rungby J. Zinc, zinc transporters and diabetes. Diabetologia. 2010;53(8):1549–1551. doi: 10.1007/s00125-010-1793-x.
    1. Chistiakov DA, Voronova NV. Zn2 + −transporter-8: A dual role in diabetes. Biofactors. 2009;35(4):356–363. doi: 10.1002/biof.49.
    1. Kawasaki E. ZnT8 and type 1 diabetes. Endocr J. 2012;59(7):531–537. doi: 10.1507/endocrj.EJ12-0069.
    1. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27(5):1218–1224. doi: 10.2337/diacare.27.5.1218.
    1. Alvarez Guisasola F, Tofe Povedano S, Krishnarajah G, Lyu R, Mavros P, Yin D. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study. Diabetes Obes Metab. 2008;10(Suppl 1):25–32. doi: 10.1111/j.1463-1326.2008.00882.x.
    1. Odegard PS, Capoccia K. Medication taking and diabetes: a systematic review of the literature. Diabetes Educ. 2007;33(6):1014–1029. doi: 10.1177/0145721707308407.
    1. Grant RW, Devita NG, Singer DE, Meigs JB. Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes Care. 2003;26(5):1408–1412. doi: 10.2337/diacare.26.5.1408.
    1. Bailey CJ, Kodack M. Patient adherence to medication requirements for therapy of type 2 diabetes. Int J Clin Pract. 2011;65(3):314–322. doi: 10.1111/j.1742-1241.2010.02544.x.
    1. Dham S, Shah V, Hirsch S, Banerji MA. The role of complementary and alternative medicine in diabetes. Curr Diab Rep. 2006;6(3):251–258. doi: 10.1007/s11892-006-0042-7.
    1. Sakurai H, Adachi Y. The pharmacology of the insulinomimetic effect of zinc complexes. Biometals. 2005;18(4):319–323. doi: 10.1007/s10534-005-3688-8.
    1. Sakurai H, Katoh A, Kiss T, Jakusch T, Hattori M. Metallo-allixinate complexes with anti-diabetic and anti-metabolic syndrome activities. Metallomics. 2010;2(10):670–682. doi: 10.1039/c0mt00025f.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться